Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Meyer

Showing results (461-470 of 476) with videos related to

Pageof 48
Sort By:
Annals of Surgery|December 5, 2019
Primary Open Versus Closed Implantation Strategy for Totally Implantable Venous Access Ports: The Multicentre Randomized Controlled PORTAS-3 Trial (DRKS 00004900)Felix J Hüttner, Tom Bruckner, Matthes Hackbusch, et al.
Brain Communications|May 24, 2023
Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosisWolfgang P Ruf, Matej Boros, Axel Freischmidt, et al.
Annals of Neurology|August 9, 2025
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral SclerosisChristina Steffke, Karthik Baskar, Franziska Bachhuber, et al.
Biorxiv : the Preprint Server for Biology|August 2, 2024
Transfer RNA acetylation regulates in vivo mammalian stress signalingSupuni Thalalla Gamage, Roxane Khoogar, Shereen Howpay Manage, et al.
Nature Neuroscience|March 25, 2015
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementiaAxel Freischmidt, Thomas Wieland, Benjamin Richter, et al.
Journal of Affective Disorders|July 13, 2025
Considerations in the development of learning health networks for mood disordersJessica M Lipschitz, Caleb Adler, Jorge Almeida, et al.
Eclinicalmedicine|February 22, 2024
Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access programMaximilian Wiesenfarth, Johannes Dorst, David Brenner, et al.
Neurological Research and Practice|July 3, 2024
Patients' and caregivers' perception of multidimensional and palliative care in amyotrophic lateral sclerosis - protocol of a German multicentre studyKatharina Linse, Constanze Weber, Peter Reilich, et al.
Brain : a Journal of Neurology|January 18, 2018
Hot-spot KIF5A mutations cause familial ALSDavid Brenner, Rüstem Yilmaz, Kathrin Müller, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Pageof 48

Showing results (461-470 of 476) with videos related to

Sort By:
Pageof 48
Annals of Surgery|December 5, 2019
Primary Open Versus Closed Implantation Strategy for Totally Implantable Venous Access Ports: The Multicentre Randomized Controlled PORTAS-3 Trial (DRKS 00004900)Felix J Hüttner, Tom Bruckner, Matthes Hackbusch, et al.
Brain Communications|May 24, 2023
Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosisWolfgang P Ruf, Matej Boros, Axel Freischmidt, et al.
Annals of Neurology|August 9, 2025
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral SclerosisChristina Steffke, Karthik Baskar, Franziska Bachhuber, et al.
Biorxiv : the Preprint Server for Biology|August 2, 2024
Transfer RNA acetylation regulates in vivo mammalian stress signalingSupuni Thalalla Gamage, Roxane Khoogar, Shereen Howpay Manage, et al.
Nature Neuroscience|March 25, 2015
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementiaAxel Freischmidt, Thomas Wieland, Benjamin Richter, et al.
Journal of Affective Disorders|July 13, 2025
Considerations in the development of learning health networks for mood disordersJessica M Lipschitz, Caleb Adler, Jorge Almeida, et al.
Eclinicalmedicine|February 22, 2024
Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access programMaximilian Wiesenfarth, Johannes Dorst, David Brenner, et al.
Neurological Research and Practice|July 3, 2024
Patients' and caregivers' perception of multidimensional and palliative care in amyotrophic lateral sclerosis - protocol of a German multicentre studyKatharina Linse, Constanze Weber, Peter Reilich, et al.
Brain : a Journal of Neurology|January 18, 2018
Hot-spot KIF5A mutations cause familial ALSDavid Brenner, Rüstem Yilmaz, Kathrin Müller, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Pageof 48